Ann: Appendix 4E and FY21 Financial Report, page-61

Congratulations to the CEO and the skilled staff working at Cellmid/ Advangen for being able to develop, test, manufacture and bring to market the first of several new products as outlined above; the results of many years hard work while being yelled at continuously for not taking into account misguided shareholders self imposed restrictive time frames.
Operating under the duress of covid restrictions, supply chain upheavals, the rotation of the market aiming point by about 90 degrees, and all of the above seemingly endless vitriol, the ability to do this is quite remarkable.
Well done